MACROGENICS INC - 8-K Filing

MacroGenics reports Q3 2026 net loss of $20.1 million and maintains cash runway through 2028 with $287.7 million in liquidity.

SEC EDGAR · November 12, 2026, 21:11 UTC

Tickers: $MGNX

More Regulatory news

Stark Novus Financial Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:44 UTC
Starling Oncology, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:43 UTC
Spero Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:43 UTC
BATTALION OIL CORP - 10-Q Filing SEC EDGAR · November 12, 2026, 21:43 UTC
INNOVATIVE FOOD HOLDINGS INC - 10-Q Filing SEC EDGAR · November 12, 2026, 21:42 UTC
Silexion Therapeutics Corp - 10-Q Filing SEC EDGAR · November 12, 2026, 21:42 UTC
DiaMedica Therapeutics Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:42 UTC
BATTALION OIL CORP - 8-K Filing SEC EDGAR · November 12, 2026, 21:41 UTC
Algorhythm Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 21:42 UTC
AMERICAN BATTERY MATERIALS, INC. - 10-Q Filing SEC EDGAR · November 12, 2026, 21:41 UTC